Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

Author:

Russo Domenico1,Martinelli Giovanni2,Malagola Michele1,Skert Cristina1,Soverini Simona2,Iacobucci Ilaria2,De Vivo Antonio2,Testoni Nicoletta2,Castagnetti Fausto2,Gugliotta Gabriele2,Turri Diamante3,Bergamaschi Michela4,Pregno Patrizia5,Pungolino Ester6,Stagno Fabio7,Breccia Massimo8,Martino Bruno9,Intermesoli Tamara10,Fava Carmen11,Abruzzese Elisabetta12,Tiribelli Mario13,Bigazzi Catia14,Cesana Bruno Mario15,Rosti Gianantonio2,Baccarani Michele2

Affiliation:

1. Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia, Brescia, Italy;

2. Institute of Hematology L. and A. Seràgnoli, S. Orsola Malpighi Hospital, University of Bologna, Bologna, Italy;

3. Ematologia 1-TMO, Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy;

4. Department of Hematology, University of Genoa, Genoa, Italy;

5. Hematology 2, ASO S. Giovanni Battista, Turin, Italy;

6. Division of Hematology, Department of Oncology and Hematology, Niguarda Ca' Granda Hospital, Milan, Italy;

7. Department of Clinical and Molecular Bio-Medicine, Section of Hematology, Oncology and General Pathology, University of Catania, Ferrarotto Hospital, Catania, Italy;

8. Department of Cellular Biotechnologies and Hematology, University “La Sapienza”, Rome, Italy;

9. Hematology Unit, “Bianchi-Melacrino-Morelli” Hospital, Reggio Calabria, Italy;

10. Division of Hematology, Ospedali Riuniti, Bergamo, Italy;

11. University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy;

12. Hematology, S. Eugenio Hospital, Rome, Italy;

13. Division of Hematology and Bone Marrow Transplantation, University of Udine, Udine, Italy;

14. Hematology, Mazzoni Hospital, Ascoli Piceno, Italy; and

15. Medical Statistics and Biometry Unit, Department of Biomedical Sciences and Biotechnologies, University of Brescia, Brescia, Italy

Abstract

Key Points INTERIM treatment affects cytogenetic and molecular response, but not the outcome. No patients treated with INTERIM progressed to accelerated or blast phase.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3